{
    "abstract": "Among more than 2500 nontyphoidal Salmonella enterica (NTS) serovars, S. enterica serovar Typhimurium and S. enterica serovar Enteritidis account for approximately fifty percent of all human isolates of NTS reported globally. The global incidence of NTS gastroenteritis in 2010 was estimated to be 93 million cases, approximately 80 million of which were contracted via food-borne transmission. It is estimated that 155,000 deaths resulted from NTS in 2010. NTS also causes severe, extra-intestinal, invasive bacteremia, referred to as invasive nontyphoidal Salmonella (iNTS) disease. iNTS disease usually presents as a febrile illness, frequently without gastrointestinal symptoms, in both adults and children. Symptoms of iNTS are similar to malaria, often including fever (>90%) and splenomegaly (>40%). The underlying reasons for the high rates of iNTS disease in Africa are still being elucidated. Evidence from animal and human studies supports the feasibility of developing a safe and effective vaccine against iNTS. Both antibodies and complement can kill Salmonella species in vitro. Proof-of-principle studies in animal models have demonstrated efficacy for live attenuated and subunit vaccines that target the O-antigens, flagellin proteins, and other outer membrane proteins of serovars Typhimurium and Enteritidis. More recently, a novel delivery strategy for NTS vaccines has been developed: the Generalized Modules for Membrane Antigens (GMMA) technology which presents surface polysaccharides and outer membrane proteins in their native conformation. GMMA technology is self-adjuvanting, as it delivers multiple pathogen-associated molecular pattern molecules. GMMA may be particularly relevant for low- and middle-income countries as it has the potential for high immunologic potency at a low cost and involves a relatively simple production process without the need for complex conjugation. Several vaccines for the predominant NTS serovars Typhimurium and Enteritidis, are currently under development.",
    "author_highlights": [
        {
            "endOffset": 5554,
            "sentence": "Nontyphoidal Salmonella (NTS) has a significant disease burden, especially in sub-Saharan Africa.",
            "startOffset": 5457
        },
        {
            "endOffset": 5646,
            "sentence": "Major risk factors for invasive nontyphoidal Salmonella disease are still being elucidated.",
            "startOffset": 5555
        },
        {
            "endOffset": 5734,
            "sentence": "Proof-of-principle studies have demonstrated efficacy of NTS vaccines in animal models.",
            "startOffset": 5647
        },
        {
            "endOffset": 5844,
            "sentence": "Monovalent and bivalent vaccines for Salmonella Typhimurium and Salmonella Enteritidis are under development.",
            "startOffset": 5735
        }
    ],
    "bib_entries": {
        "bib0005": null,
        "bib0010": {
            "authors": [
                {
                    "first": "Nicholas A.",
                    "initial": "N.A.",
                    "last": "Feasey"
                },
                {
                    "first": "Gordon",
                    "initial": "G.",
                    "last": "Dougan"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Kingsley"
                },
                {
                    "first": "Robert S.",
                    "initial": "R.S.",
                    "last": "Heyderman"
                },
                {
                    "first": "Melita A.",
                    "initial": "M.A.",
                    "last": "Gordon"
                }
            ],
            "doi": "10.1016/S0140-6736(11)61752-2",
            "firstpage": "2489",
            "issn": "01406736",
            "lastpage": "2499",
            "pub_year": 2012,
            "title": "Invasive non-typhoidal salmonella disease: An emerging and neglected tropical disease in Africa",
            "volume": "379"
        },
        "bib0015": {
            "authors": [
                {
                    "first": "Shannon E.",
                    "initial": "S.E.",
                    "last": "Majowicz"
                },
                {
                    "first": "Jennie",
                    "initial": "J.",
                    "last": "Musto"
                },
                {
                    "first": "Elaine",
                    "initial": "E.",
                    "last": "Scallan"
                },
                {
                    "first": "Frederick J.",
                    "initial": "F.J.",
                    "last": "Angulo"
                },
                {
                    "first": "Martyn",
                    "initial": "M.",
                    "last": "Kirk"
                },
                {
                    "first": "Sarah J.",
                    "initial": "S.J.",
                    "last": "O'Brien"
                },
                {
                    "first": "Timothy F.",
                    "initial": "T.F.",
                    "last": "Jones"
                },
                {
                    "first": "Aamir",
                    "initial": "A.",
                    "last": "Fazil"
                },
                {
                    "first": "Robert M.",
                    "initial": "R.M.",
                    "last": "Hoekstra"
                }
            ],
            "doi": "10.1086/650733",
            "firstpage": "882",
            "issn": "10584838",
            "lastpage": "889",
            "pmid": "20158401",
            "pub_year": 2010,
            "title": "The global burden of nontyphoidal salmonella gastroenteritis",
            "volume": "50"
        },
        "bib0020": {
            "authors": [
                {
                    "first": "Elizabeth A.",
                    "initial": "E.A.",
                    "last": "Reddy"
                },
                {
                    "first": "Andrea V.",
                    "initial": "A.V.",
                    "last": "Shaw"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Crump"
                }
            ],
            "doi": "10.1016/S1473-3099(10)70072-4",
            "firstpage": "417",
            "issn": "14733099",
            "lastpage": "432",
            "pmid": "20510282",
            "pub_year": 2010,
            "title": "Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis",
            "volume": "10"
        },
        "bib0025": {
            "authors": [
                {
                    "first": "Trong T.",
                    "initial": "T.T.",
                    "last": "Ao"
                },
                {
                    "first": "Nicholas A.",
                    "initial": "N.A.",
                    "last": "Feasey"
                },
                {
                    "first": "Melita A.",
                    "initial": "M.A.",
                    "last": "Gordon"
                },
                {
                    "first": "Karen H.",
                    "initial": "K.H.",
                    "last": "Keddy"
                },
                {
                    "first": "Frederick J.",
                    "initial": "F.J.",
                    "last": "Angulo"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Crump"
                }
            ],
            "doi": "10.3201/eid2106.140999",
            "firstpage": "941",
            "issn": "10806040",
            "lastpage": "949",
            "pmid": "25860298",
            "pub_year": 2015,
            "title": "Global burden of invasive nontyphoidal salmonella disease, 2010",
            "volume": "21"
        },
        "bib0030": {
            "authors": [
                {
                    "first": "Melita A.",
                    "initial": "M.A.",
                    "last": "Gordon"
                },
                {
                    "first": "Hastings T.",
                    "initial": "H.T.",
                    "last": "Banda"
                },
                {
                    "first": "Macpherson",
                    "initial": "M.",
                    "last": "Gondwe"
                },
                {
                    "first": "Stephen B.",
                    "initial": "S.B.",
                    "last": "Gordon"
                },
                {
                    "first": "Martin J.",
                    "initial": "M.J.",
                    "last": "Boeree"
                },
                {
                    "first": "Amanda L.",
                    "initial": "A.L.",
                    "last": "Walsh"
                },
                {
                    "first": "John E.",
                    "initial": "J.E.",
                    "last": "Corkill"
                },
                {
                    "first": "C. Anthony",
                    "initial": "C.A.",
                    "last": "Hart"
                },
                {
                    "first": "Charles F.",
                    "initial": "C.F.",
                    "last": "Gilks"
                },
                {
                    "first": "Malcolm E.",
                    "initial": "M.E.",
                    "last": "Molyneux"
                }
            ],
            "doi": "10.1097/00002030-200208160-00009",
            "firstpage": "1633",
            "issn": "02699370",
            "lastpage": "1641",
            "pmid": "12172085",
            "pub_year": 2002,
            "title": "Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: High mortality and frequent recrudescence",
            "volume": "16"
        },
        "bib0035": {
            "authors": [
                {
                    "first": "Sharon M.",
                    "initial": "S.M.",
                    "last": "Tennant"
                },
                {
                    "first": "Souleymane",
                    "initial": "S.",
                    "last": "Diallo"
                },
                {
                    "first": "Haim",
                    "initial": "H.",
                    "last": "Levy"
                },
                {
                    "first": "Sofie",
                    "initial": "S.",
                    "last": "Livio"
                },
                {
                    "first": "Samba O.",
                    "initial": "S.O.",
                    "last": "Sow"
                },
                {
                    "first": "Milagritos",
                    "initial": "M.",
                    "last": "Tapia"
                },
                {
                    "first": "Patricia I.",
                    "initial": "P.I.",
                    "last": "Fields"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Mikoleit"
                },
                {
                    "first": "Boubou",
                    "initial": "B.",
                    "last": "Tamboura"
                },
                {
                    "first": "Karen L.",
                    "initial": "K.L.",
                    "last": "Kotloff"
                },
                {
                    "first": "James P.",
                    "initial": "J.P.",
                    "last": "Nataro"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Galen"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1371/journal.pntd.0000621",
            "pmid": "20231882",
            "pub_year": 2010,
            "title": "Identification by PCR of non-typhoidal Salmonella enterica serovars associated with invasive infections among febrile patients in Mali",
            "volume": "4"
        },
        "bib0040": {
            "authors": [
                {
                    "first": "Calman A.",
                    "initial": "C.A.",
                    "last": "MacLennan"
                },
                {
                    "first": "Laura B.",
                    "initial": "L.B.",
                    "last": "Martin"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Micoli"
                }
            ],
            "doi": "10.4161/hv.29054",
            "firstpage": "1478",
            "issn": "21645515",
            "lastpage": "1493",
            "pmid": "24804797",
            "pub_year": 2014,
            "title": "Vaccines against invasive Salmonella disease: Current status and future directions",
            "volume": "10"
        },
        "bib0045": {
            "authors": [
                {
                    "first": "Melita A.",
                    "initial": "M.A.",
                    "last": "Gordon"
                }
            ],
            "doi": "10.1097/QCO.0b013e32834a9980",
            "firstpage": "484",
            "issn": "09517375",
            "lastpage": "489",
            "pmid": "21844803",
            "pub_year": 2011,
            "title": "Invasive nontyphoidal Salmonella disease: Epidemiology, pathogenesis and diagnosis",
            "volume": "24"
        },
        "bib0050": {
            "authors": [
                {
                    "first": "Calman A.",
                    "initial": "C.A.",
                    "last": "MacLennan"
                },
                {
                    "first": "Esther N.",
                    "initial": "E.N.",
                    "last": "Gondwe"
                },
                {
                    "first": "Chisomo L.",
                    "initial": "C.L.",
                    "last": "Msefula"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Kingsley"
                },
                {
                    "first": "Nicholas R.",
                    "initial": "N.R.",
                    "last": "Thomson"
                },
                {
                    "first": "Sarah A.",
                    "initial": "S.A.",
                    "last": "White"
                },
                {
                    "first": "Margaret",
                    "initial": "M.",
                    "last": "Goodall"
                },
                {
                    "first": "Derek J.",
                    "initial": "D.J.",
                    "last": "Pickard"
                },
                {
                    "first": "Stephen M.",
                    "initial": "S.M.",
                    "last": "Graham"
                },
                {
                    "first": "Gordon",
                    "initial": "G.",
                    "last": "Dougan"
                },
                {
                    "first": "C. Anthony",
                    "initial": "C.A.",
                    "last": "Hart"
                },
                {
                    "first": "Malcolm E.",
                    "initial": "M.E.",
                    "last": "Molyneux"
                },
                {
                    "first": "Mark T.",
                    "initial": "M.T.",
                    "last": "Drayson"
                }
            ],
            "doi": "10.1172/JCI33998",
            "firstpage": "1553",
            "issn": "00219738",
            "lastpage": "1562",
            "pmid": "18357343",
            "pub_year": 2008,
            "title": "The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children",
            "volume": "118"
        },
        "bib0055": null,
        "bib0060": {
            "authors": [
                {
                    "first": "Matthew K.",
                    "initial": "M.K.",
                    "last": "Siggins"
                },
                {
                    "first": "Adam F.",
                    "initial": "A.F.",
                    "last": "Cunningham"
                },
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "Marshall"
                },
                {
                    "first": "Jayne L.",
                    "initial": "J.L.",
                    "last": "Chamberlain"
                },
                {
                    "first": "Ian R.",
                    "initial": "I.R.",
                    "last": "Henderson"
                },
                {
                    "first": "Calman A.",
                    "initial": "C.A.",
                    "last": "MacLennan"
                }
            ],
            "doi": "10.4049/jimmunol.1000284",
            "firstpage": "2365",
            "issn": "00221767",
            "lastpage": "2371",
            "pmid": "21217014",
            "pub_year": 2011,
            "title": "Absent bactericidal activity of mouse serum against invasive african nontyphoidal Salmonella results from impaired complement function but not a lack of antibody",
            "volume": "186"
        },
        "bib0065": {
            "authors": [
                {
                    "first": "Mary Adetinuke",
                    "initial": "M.A.",
                    "last": "Boyd"
                },
                {
                    "first": "Sharon M.",
                    "initial": "S.M.",
                    "last": "Tennant"
                },
                {
                    "first": "Venant A.",
                    "initial": "V.A.",
                    "last": "Saague"
                },
                {
                    "first": "Raphael",
                    "initial": "R.",
                    "last": "Simon"
                },
                {
                    "first": "Khitam",
                    "initial": "K.",
                    "last": "Muhsen"
                },
                {
                    "first": "Girish",
                    "initial": "G.",
                    "last": "Ramachandran"
                },
                {
                    "first": "Alan S.",
                    "initial": "A.S.",
                    "last": "Cross"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Galen"
                },
                {
                    "first": "Marcela F.",
                    "initial": "M.F.",
                    "last": "Pasetti"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1128/CVI.00115-14",
            "firstpage": "712",
            "issn": "15566811",
            "lastpage": "721",
            "pmid": "24623629",
            "pub_year": 2014,
            "title": "Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines",
            "volume": "21"
        },
        "bib0070": {
            "authors": [
                {
                    "first": "Raphael",
                    "initial": "R.",
                    "last": "Simon"
                },
                {
                    "first": "Jin Y.",
                    "initial": "J.Y.",
                    "last": "Wang"
                },
                {
                    "first": "Mary A.",
                    "initial": "M.A.",
                    "last": "Boyd"
                },
                {
                    "first": "Mohan E.",
                    "initial": "M.E.",
                    "last": "Tulapurkar"
                },
                {
                    "first": "Girish",
                    "initial": "G.",
                    "last": "Ramachandran"
                },
                {
                    "first": "Sharon M.",
                    "initial": "S.M.",
                    "last": "Tennant"
                },
                {
                    "first": "Marcela",
                    "initial": "M.",
                    "last": "Pasetti"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Galen"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1371/journal.pone.0064680",
            "issn": "19326203",
            "pmid": "23741368",
            "pub_year": 2013,
            "title": "Sustained Protection in Mice Immunized with Fractional Doses of Salmonella Enteritidis Core and O Polysaccharide-Flagellin Glycoconjugates",
            "volume": "8"
        },
        "bib0075": {
            "authors": [
                {
                    "first": "Alida",
                    "initial": "A.",
                    "last": "Ault"
                },
                {
                    "first": "Sharon M.",
                    "initial": "S.M.",
                    "last": "Tennant"
                },
                {
                    "first": "J. Patrick",
                    "initial": "J.P.",
                    "last": "Gorres"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Eckhaus"
                },
                {
                    "first": "Netanya G.",
                    "initial": "N.G.",
                    "last": "Sandler"
                },
                {
                    "first": "Annelys",
                    "initial": "A.",
                    "last": "Roque"
                },
                {
                    "first": "Sofie",
                    "initial": "S.",
                    "last": "Livio"
                },
                {
                    "first": "Saran",
                    "initial": "S.",
                    "last": "Bao"
                },
                {
                    "first": "Kathryn E.",
                    "initial": "K.E.",
                    "last": "Foulds"
                },
                {
                    "first": "Shing Fen",
                    "initial": "S.F.",
                    "last": "Kao"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Roederer"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Schmidlein"
                },
                {
                    "first": "Mary Adetinuke",
                    "initial": "M.A.",
                    "last": "Boyd"
                },
                {
                    "first": "Marcela F.",
                    "initial": "M.F.",
                    "last": "Pasetti"
                },
                {
                    "first": "Daniel C.",
                    "initial": "D.C.",
                    "last": "Douek"
                },
                {
                    "first": "Jacob D.",
                    "initial": "J.D.",
                    "last": "Estes"
                },
                {
                    "first": "Gary J.",
                    "initial": "G.J.",
                    "last": "Nabel"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Srinivas S.",
                    "initial": "S.S.",
                    "last": "Rao"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.09.041",
            "firstpage": "5879",
            "issn": "0264410X",
            "lastpage": "5888",
            "pmid": "24099872",
            "pub_year": 2013,
            "title": "Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates",
            "volume": "31"
        },
        "bib0080": {
            "authors": [
                {
                    "first": "D. C.",
                    "initial": "D.C.",
                    "last": "Watson"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Robbins"
                },
                {
                    "first": "S. C.",
                    "initial": "S.C.",
                    "last": "Szu"
                }
            ],
            "firstpage": "4679",
            "issn": "00199567",
            "lastpage": "4686",
            "pmid": "1383154",
            "pub_year": 1992,
            "title": "Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine",
            "volume": "60"
        },
        "bib0085": {
            "authors": [
                {
                    "first": "Simona",
                    "initial": "S.",
                    "last": "Rondini"
                },
                {
                    "first": "Luisa",
                    "initial": "L.",
                    "last": "Lanzilao"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Necchi"
                },
                {
                    "first": "Colette M.",
                    "initial": "C.M.",
                    "last": "O'Shaughnessy"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Micoli"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                },
                {
                    "first": "Calman A.",
                    "initial": "C.A.",
                    "last": "MacLennan"
                }
            ],
            "doi": "10.1016/j.micpath.2013.05.014",
            "firstpage": "19",
            "issn": "08824010",
            "lastpage": "23",
            "pmid": "23756206",
            "pub_year": 2013,
            "title": "Invasive african salmonella typhimurium induces bactericidal antibodies against O-antigens",
            "volume": "63"
        },
        "bib0090": {
            "authors": [
                {
                    "first": "Christiane",
                    "initial": "C.",
                    "last": "Gerke"
                },
                {
                    "first": "Anna Maria",
                    "initial": "A.M.",
                    "last": "Colucci"
                },
                {
                    "first": "Carlo",
                    "initial": "C.",
                    "last": "Giannelli"
                },
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Sanzone"
                },
                {
                    "first": "Claudia Giorgina",
                    "initial": "C.G.",
                    "last": "Vitali"
                },
                {
                    "first": "Luigi",
                    "initial": "L.",
                    "last": "Sollai"
                },
                {
                    "first": "Omar",
                    "initial": "O.",
                    "last": "Rossi"
                },
                {
                    "first": "Laura B.",
                    "initial": "L.B.",
                    "last": "Martin"
                },
                {
                    "first": "Jochen",
                    "initial": "J.",
                    "last": "Auerbach"
                },
                {
                    "first": "Vito",
                    "initial": "V.",
                    "last": "Di Cioccio"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                }
            ],
            "doi": "10.1371/journal.pone.0134478",
            "issn": "19326203",
            "pmid": "26248044",
            "pub_year": 2015,
            "title": "Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB",
            "volume": "10"
        },
        "bib0095": {
            "authors": [
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Gil-Cruz"
                },
                {
                    "first": "Saeeda",
                    "initial": "S.",
                    "last": "Bobat"
                },
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "Marshall"
                },
                {
                    "first": "Robert A.",
                    "initial": "R.A.",
                    "last": "Kingsley"
                },
                {
                    "first": "Ewan A.",
                    "initial": "E.A.",
                    "last": "Ross"
                },
                {
                    "first": "Ian R.",
                    "initial": "I.R.",
                    "last": "Henderson"
                },
                {
                    "first": "Denisse L.",
                    "initial": "D.L.",
                    "last": "Leyton"
                },
                {
                    "first": "Ruth E.",
                    "initial": "R.E.",
                    "last": "Coughlan"
                },
                {
                    "first": "Mahmood",
                    "initial": "M.",
                    "last": "Khan"
                },
                {
                    "first": "Karina T.",
                    "initial": "K.T.",
                    "last": "Jensen"
                },
                {
                    "first": "Christopher D.",
                    "initial": "C.D.",
                    "last": "Buckley"
                },
                {
                    "first": "Gordon",
                    "initial": "G.",
                    "last": "Dougan"
                },
                {
                    "first": "Ian C.M.",
                    "initial": "I.C.M.",
                    "last": "MacLennan"
                },
                {
                    "first": "Constantino",
                    "initial": "C.",
                    "last": "L\u00f3pez-Mac\u00edas"
                },
                {
                    "first": "Adam F.",
                    "initial": "A.F.",
                    "last": "Cunningham"
                }
            ],
            "doi": "10.1073/pnas.0812431106",
            "firstpage": "9803",
            "issn": "00278424",
            "lastpage": "9808",
            "pmid": "19487686",
            "pub_year": 2009,
            "title": "The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response",
            "volume": "106"
        },
        "bib0100": {
            "authors": [
                {
                    "first": "Calman A.",
                    "initial": "C.A.",
                    "last": "Maclennan"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                }
            ],
            "doi": "10.1586/eri.13.27",
            "firstpage": "443",
            "issn": "14787210",
            "lastpage": "446",
            "pmid": "23627848",
            "pub_year": 2013,
            "title": "Invasive nontyphoidal Salmonella disease in Africa: Current status",
            "volume": "11"
        }
    },
    "body_text": [
        {
            "endOffset": 16074,
            "parents": [],
            "secId": "sec0010",
            "sentence": "This schedule will allow for programmatic introduction, as well as will enable children to be protected at an earlier age when they are at higher risk of disease.",
            "startOffset": 15912,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 17233,
            "parents": [],
            "refoffsets": {
                "bib0060": {
                    "endOffset": 17232,
                    "startOffset": 17228
                }
            },
            "secId": "sec0015",
            "sentence": "There are important differences to consider between mouse and human infections, such as the inability of mouse complement to kill NTS in vitro [12].",
            "startOffset": 17085,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 21229,
            "parents": [],
            "refoffsets": {
                "bib0070": {
                    "endOffset": 21228,
                    "startOffset": 21224
                }
            },
            "secId": "sec0020",
            "sentence": "Salmonella Enteritidis COPS-FliC conjugates were able to elicit protective antibodies in preclinical studies with both components of the conjugate eliciting Salmonella-specific immunity and protection maintained at very low vaccine doses [14].",
            "startOffset": 20986,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 14830,
            "parents": [],
            "secId": "sec0010",
            "sentence": "GMMA may be particularly relevant for low- and middle-income countries as it has the potential for high immunologic potency at a low cost and involves a relatively simple production process without the need for complex conjugation.",
            "startOffset": 14599,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 22048,
            "parents": [],
            "secId": "sec0020",
            "sentence": "In mice, NTS GMMA vaccines are at least as immunogenic at comparable doses of O-antigen glycoconjugate vaccines (NVGH, unpublished data).",
            "startOffset": 21911,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 21696,
            "parents": [],
            "secId": "sec0020",
            "sentence": "The institute's current efforts are focused on the advancement of the GMMA platform for Gram-negative bacteria, including NTS vaccine production.",
            "startOffset": 21551,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 22448,
            "parents": [],
            "secId": "sec0020",
            "sentence": "The NVGH bivalent conjugate vaccine is available for further development if the GMMA platform does not perform as expected.",
            "startOffset": 22325,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 18331,
            "parents": [],
            "refoffsets": {
                "bib0065": {
                    "endOffset": 18330,
                    "startOffset": 18323
                },
                "bib0070": {
                    "endOffset": 18330,
                    "startOffset": 18323
                }
            },
            "secId": "sec0020",
            "sentence": "It is unclear if these vaccine candidates will be protective against both gastroenteritis and invasive disease, but it has been proposed that a multivalent vaccine that targets 5\u20136 serovars could protect against the most relevant forms of gastroenteritis and invasive Salmonella worldwide [13,14].",
            "startOffset": 18034,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 20464,
            "parents": [],
            "secId": "sec0020",
            "sentence": "It is hypothesized that by using a Salmonella protective protein antigen instead of a heterologous pathogen protein (e.g., tetanus toxoid, CRM197), enhanced efficacy may be achieved as antibodies would be directed towards two independent protective targets on the bacterial surface.",
            "startOffset": 20182,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 15415,
            "parents": [],
            "secId": "sec0010",
            "sentence": "However, manufacturing complexities in purifying outer membrane proteins with the appropriate conformation may obviate the utility of porins as immunogens.",
            "startOffset": 15260,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 17851,
            "parents": [],
            "refoffsets": {
                "bib0040": {
                    "endOffset": 17850,
                    "startOffset": 17847
                },
                "bib0075": {
                    "endOffset": 17764,
                    "startOffset": 17760
                }
            },
            "secId": "sec0015",
            "sentence": "In vitro assays are available to quantify the serum bactericidal activity (SBA) of antibodies induced by Salmonella Typhimurium and Salmonella Enteritidis infection [15] and to assess the opsonophagocytic killing activity of anti-Salmonella antibodies [8].",
            "startOffset": 17595,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 13932,
            "parents": [],
            "secId": "sec0010",
            "sentence": "Proof-of-principle studies have demonstrated efficacy, in animal models, of live-attenuated and subunit vaccines that target the O-antigens, flagellin proteins, and other outer membrane proteins of Salmonella Typhimurium and Salmonella Enteritidis.",
            "startOffset": 13684,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 22204,
            "parents": [],
            "refoffsets": {
                "bib0090": {
                    "endOffset": 22203,
                    "startOffset": 22199
                }
            },
            "secId": "sec0020",
            "sentence": "Salmonella GMMA reactogenicity remains to be evaluated in humans; however, Shigella sonnei GMMA was safe and immunogenic in a Phase 1 trial in adults [18].",
            "startOffset": 22049,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 23990,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Funding for research to date has come from the Wellcome Trust, the Bill & Melinda Gates Foundation and NIH, but progress through clinical development, especially large Phase 3 efficacy trials, will require funding from a variety of sources, including vaccine-manufacturing partners in potential target markets.",
            "startOffset": 23680,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 15911,
            "parents": [],
            "secId": "sec0010",
            "sentence": "Programmatic field implementation in children could integrate directly with existing Expanded Program on Immunization schedules, potentially at 6, 10, and 14 weeks, or at 9 months concomitant with measles vaccination.",
            "startOffset": 15694,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 24506,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Drs. Tennant and Simon are inventors on the following US patents: \u201cBroad spectrum vaccine against non-typhoidal Salmonella\u201d (patent number 9,050,283) and \u201cBroad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease\u201d (patent number 9,011,871); Dr. MacLennan is a former employee of the Novartis Vaccines Institute for Global Health and recipient of a Clinical Research Fellowship from GlaxoSmithKline; Dr. Martin is an employee of GSK; Dr. Khan declares no conflict of interest.",
            "startOffset": 24011,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 23529,
            "parents": [],
            "secId": "sec0025",
            "sentence": "It has been proposed that until bacterial bloodstream infections are recognized as a distinct cause of mortality, iNTS disease will remain a significant, but neglected, disease of developing countries.",
            "startOffset": 23328,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 14598,
            "parents": [],
            "secId": "sec0010",
            "sentence": "GMMA technology is self-adjuvanting, as it delivers multiple pathogen-associated molecular pattern molecules.",
            "startOffset": 14489,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 22615,
            "parents": [],
            "refoffsets": {
                "bib0095": {
                    "endOffset": 22614,
                    "startOffset": 22610
                }
            },
            "secId": "sec0020",
            "sentence": "The University of Birmingham has proposed a different protein-based vaccine candidate consisting of outer membrane protein D (OmpD), purified from whole bacteria [19].",
            "startOffset": 22448,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 22754,
            "parents": [],
            "secId": "sec0020",
            "sentence": "Studies of porin-deficient bacteria showed that OmpD (absent in Salmonella Typhi) is a viable target for antibody protection against iNTS.",
            "startOffset": 22616,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 18710,
            "parents": [],
            "secId": "sec0020",
            "sentence": "The Center for Vaccine Development at the University of Maryland, Baltimore (UMB) is developing live-attenuated, oral vaccines for both Salmonella Typhimurium (CVD 1931, derived from a wild-type Salmonella Typhimurium strain from the ST313 genotype circulating in sub-Saharan Africa) and Salmonella Enteritidis (CVD 1944, derived from wild-type invasive Salmonella Enteritidis).",
            "startOffset": 18332,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 12894,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Both antibodies and complement can kill Salmonella species in vitro.",
            "startOffset": 12826,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 23327,
            "parents": [],
            "refoffsets": {
                "bib0100": {
                    "endOffset": 23326,
                    "startOffset": 23322
                }
            },
            "secId": "sec0025",
            "sentence": "iNTS disease has yet to be recognized as a major priority for vaccine development either by global health policy institutions or funding agencies, even though there is a significant burden of childhood mortality associated with this disease [20].",
            "startOffset": 23081,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 13440,
            "parents": [],
            "refoffsets": {
                "bib0050": {
                    "endOffset": 13439,
                    "startOffset": 13435
                }
            },
            "secId": "sec0005",
            "sentence": "However, one African study found that high antibody titers against Salmonella lipopolysaccharide (LPS) O-antigen were associated with impaired in vitro serum killing of Salmonella Typhimurium in a proportion of HIV-infected Malawian adults [10].",
            "startOffset": 13195,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 19893,
            "parents": [],
            "secId": "sec0020",
            "sentence": "This O:4-TT conjugate vaccine was able to protect mice against lethal challenge with wild-type Salmonella Typhimurium.",
            "startOffset": 19775,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 16670,
            "parents": [],
            "secId": "sec0015",
            "sentence": "There are relatively robust animal models that can be used to evaluate preclinical data.",
            "startOffset": 16582,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 19280,
            "parents": [],
            "secId": "sec0020",
            "sentence": "Microscience Limited has published results from the only live attenuated NTS vaccine candidate to be tested in humans.",
            "startOffset": 19162,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 20181,
            "parents": [],
            "secId": "sec0020",
            "sentence": "UMB has developed a bivalent, NTS conjugate vaccine candidate that covalently links the core and O-polysaccharides (COPS; both core and O polysaccharide are components of LPS) of Salmonella Typhimurium and Salmonella Enteritidis to the homologous Phase 1 flagellin subunits, respectively.",
            "startOffset": 19893,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 12717,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Effective Salmonella Typhi vaccines have been successfully licensed and administered to millions of people.",
            "startOffset": 12610,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 19586,
            "parents": [],
            "secId": "sec0020",
            "sentence": "A Phase 1 clinical trial of this product found there to be prolonged stool shedding of the vaccine strain in healthy volunteers for up to 23 days.",
            "startOffset": 19440,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 20844,
            "parents": [],
            "secId": "sec0020",
            "sentence": "UMB has created reagent strains of Salmonella Typhimurium and Salmonella Enteritidis that hyper-express flagellin that are valuable for the economical and safe purification of components for the NTS COPS-FliC conjugate vaccines.",
            "startOffset": 20616,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 16863,
            "parents": [],
            "secId": "sec0015",
            "sentence": "Mice, for example, are permissive to Salmonella Typhimurium and Salmonella Enteritidis systemic infection that begins via entry through the gut mucosa and spreads through the lymphatic system.",
            "startOffset": 16671,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 14255,
            "parents": [],
            "secId": "sec0010",
            "sentence": "The subunit glycoconjugation approach specifically links LPS-derived O polysaccharide to carrier proteins and has been successful as, unlike Salmonella Typhi, the NTS are not encapsulated.",
            "startOffset": 14067,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 18986,
            "parents": [],
            "secId": "sec0020",
            "sentence": "These attenuated strains induce seroconversion (four-fold or greater antibody titer rise) of functional anti-LPS and anti-flagellin antibodies and are also expected to elicit robust cell-mediated immunity, a key component required for the resolution of Salmonella infections.",
            "startOffset": 18711,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 19439,
            "parents": [],
            "secId": "sec0020",
            "sentence": "The vaccine, WT05, is derived from a gastroenteritis-associated strain of Salmonella Typhimurium and is attenuated by deletion of the aroC and the ssaV genes.",
            "startOffset": 19281,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 23679,
            "parents": [],
            "secId": "sec0025",
            "sentence": "Although typhoid conjugate vaccines were designated a priority by the GAVI Alliance in 2008, no such steps have been taken for vaccines against iNTS.",
            "startOffset": 23530,
            "title": "Likelihood for financing"
        },
        {
            "endOffset": 17594,
            "parents": [],
            "refoffsets": {
                "bib0050": {
                    "endOffset": 17593,
                    "startOffset": 17589
                }
            },
            "secId": "sec0015",
            "sentence": "Although immunologic correlates of protection have not yet been identified, data from Malawi have shown that acquisition of circulating antibodies to Salmonella Typhimurium, including the surface lipopolysaccharide, is associated with a lower risk of NTS bacteremia, particularly in the first few months of life when maternal antibodies are still present [10].",
            "startOffset": 17234,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 16947,
            "parents": [],
            "secId": "sec0015",
            "sentence": "In untreated mice, infection manifests as invasive disease without gastroenteritis.",
            "startOffset": 16864,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 16581,
            "parents": [],
            "secId": "sec0015",
            "sentence": "Although no such pathway is available for NTS vaccines, the experience with typhoid vaccines may serve as a good model to adapt.",
            "startOffset": 16453,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 19774,
            "parents": [],
            "refoffsets": {
                "bib0080": {
                    "endOffset": 19773,
                    "startOffset": 19769
                }
            },
            "secId": "sec0020",
            "sentence": "In 1992, the US National Institutes of Health (NIH) published pre-clinical research on an NTS conjugate vaccine for Salmonella Typhimurium that linked O:4 to tetanus toxoid (O:4-TT) [16].",
            "startOffset": 19587,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 14488,
            "parents": [],
            "secId": "sec0010",
            "sentence": "More recently, a novel delivery strategy for NTS vaccines has been developed: the Generalized Modules for Membrane Antigens (GMMA) technology presents surface polysaccharides and outer membrane proteins in their native conformation.",
            "startOffset": 14256,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 14066,
            "parents": [],
            "secId": "sec0010",
            "sentence": "The relatively poor immunogenicity of purified O-antigens can be significantly enhanced through chemical linkage to carrier proteins.",
            "startOffset": 13933,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 15693,
            "parents": [],
            "secId": "sec0010",
            "sentence": "Vaccines for iNTS will also need to target 2-4 month old infants, before the peak incidence at age 12 months.",
            "startOffset": 15584,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 15584,
            "parents": [],
            "secId": "sec0010",
            "sentence": "Other promising vaccine approaches against iNTS disease include live attenuated candidates, which can be delivered orally and induce robust mucosal and T cell immunity.",
            "startOffset": 15416,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 21328,
            "parents": [],
            "secId": "sec0020",
            "sentence": "This vaccine is being advanced in partnership with Bharat Biotech of India and the Wellcome Trust.",
            "startOffset": 21230,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 19162,
            "parents": [],
            "refoffsets": {
                "bib0075": {
                    "endOffset": 19161,
                    "startOffset": 19157
                }
            },
            "secId": "sec0020",
            "sentence": "Furthermore, CVD 1921, a prototype attenuated Salmonella Typhimurium vaccine strain, has been shown to be safe and well-tolerated in immunocompromised non-human primates [15].",
            "startOffset": 18987,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 18033,
            "parents": [],
            "secId": "sec0020",
            "sentence": "Several vaccines for Salmonella Typhimurium and Salmonella Enteritidis are under development, some of which are bivalent for both serovars (Table 1).",
            "startOffset": 17884,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 23056,
            "parents": [],
            "secId": "sec0020",
            "sentence": "It should be noted that several other vaccines against Salmonella Typhimurium and Salmonella Enteritidis are available and/or under development for use in veterinary medicine and commercial food production, particularly in the raising of livestock and other key animal carriers, most notably chickens.",
            "startOffset": 22755,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 16280,
            "parents": [],
            "secId": "sec0010",
            "sentence": "In higher income countries, NTS vaccines could also target the elderly who experience a high case-fatality rate of up to 50%.",
            "startOffset": 16155,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 16154,
            "parents": [],
            "secId": "sec0010",
            "sentence": "Vaccine implementation would likely also include populations infected with HIV.",
            "startOffset": 16075,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 15259,
            "parents": [],
            "secId": "sec0010",
            "sentence": "A reverse vaccinology approach using bioinformatics analysis of whole genome sequences from clinically important serovars may facilitate identification of additional conserved antigens.",
            "startOffset": 15074,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 21550,
            "parents": [],
            "refoffsets": {
                "bib0085": {
                    "endOffset": 21549,
                    "startOffset": 21545
                }
            },
            "secId": "sec0020",
            "sentence": "The Novartis Vaccines Institute for Global Health (NVGH, a GSK company) has also developed a bivalent O-antigen polysaccharide-CRM197 conjugate vaccine targeting both Salmonella Typhimurium and Salmonella Enteritidis [17].",
            "startOffset": 21328,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 21910,
            "parents": [],
            "secId": "sec0020",
            "sentence": "Bacterial genetic modifications are introduced into Salmonella Typhimurium and Salmonella Enteritidis parent strains to increase membrane blebbing of small (50\u201390 nm) immunogenic particles and to detoxify lipid A.",
            "startOffset": 21697,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 13607,
            "parents": [],
            "refoffsets": {
                "bib0045": {
                    "endOffset": 13606,
                    "startOffset": 13600
                },
                "bib0050": {
                    "endOffset": 13606,
                    "startOffset": 13600
                }
            },
            "secId": "sec0005",
            "sentence": "The in vivo significance of this observation is not clear, as anti-LPS antibodies have bactericidal activity, protecting against NTS challenge in mouse models [9,10].",
            "startOffset": 13441,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 22324,
            "parents": [],
            "secId": "sec0020",
            "sentence": "The ease of manufacturing GMMA and its dose-sparing potential has influenced NVGH's vaccine development prioritization.",
            "startOffset": 22205,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 15073,
            "parents": [],
            "secId": "sec0010",
            "sentence": "The development of recombinant or purified protein vaccines based on surface or outer membrane protein antigens, such as flagellin and porins OmpC, F and D offer the potential for broad-spectrum coverage due to targeting of conserved antigens.",
            "startOffset": 14830,
            "title": "General approaches to vaccine development for low- and middle-income markets"
        },
        {
            "endOffset": 20615,
            "parents": [],
            "secId": "sec0020",
            "sentence": "It has been shown that flagellin elicits a robust antibody response and that flagellin alone is protective in a mouse model of invasive NTS infection.",
            "startOffset": 20465,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 12825,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Evidence from animal and human studies supports the feasibility of vaccine development against NTS as well.",
            "startOffset": 12718,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 13194,
            "parents": [],
            "refoffsets": {
                "bib0045": {
                    "endOffset": 13193,
                    "startOffset": 13187
                },
                "bib0050": {
                    "endOffset": 13193,
                    "startOffset": 13187
                }
            },
            "secId": "sec0005",
            "sentence": "Epidemiologic studies in sub-Saharan Africa have shown that the development of antibodies against NTS corresponds with a decrease in age-related incidence of iNTS disease, and that serum antibodies have corresponding in vitro bactericidal activity partly by mediating intracellular oxidation [9,10].",
            "startOffset": 12895,
            "title": "Biological feasibility for vaccine development"
        },
        {
            "endOffset": 16452,
            "parents": [],
            "refoffsets": {
                "bib0055": {
                    "endOffset": 16446,
                    "startOffset": 16442
                },
                "bib0060": {
                    "endOffset": 16451,
                    "startOffset": 16447
                }
            },
            "secId": "sec0015",
            "sentence": "In 2013, the World Health Organization provided guidance on the regulation and prequalification of typhoid conjugate vaccines [11] [12].",
            "startOffset": 16316,
            "title": "Technical and regulatory assessment"
        },
        {
            "endOffset": 20985,
            "parents": [],
            "secId": "sec0020",
            "sentence": "UMB has also developed high-yield, low-cost methods to biochemically purify COPS and flagellin from liquid growth cultures of these strains.",
            "startOffset": 20845,
            "title": "Status of vaccine R&D activities"
        },
        {
            "endOffset": 17084,
            "parents": [],
            "secId": "sec0015",
            "sentence": "To produce an NTS enterocolitis infection, mice must be pre-treated with streptomycin or other antibiotics prior to bacterial challenge.",
            "startOffset": 16948,
            "title": "Technical and regulatory assessment"
        }
    ],
    "docId": "S0264410X1630069X",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": null,
                "first": "Sharon M.",
                "initial": "S.M.",
                "last": "Tennant"
            },
            {
                "email": null,
                "first": "Calman A.",
                "initial": "C.A.",
                "last": "MacLennan"
            },
            {
                "email": null,
                "first": "Raphael",
                "initial": "R.",
                "last": "Simon"
            },
            {
                "email": null,
                "first": "Laura B.",
                "initial": "L.B.",
                "last": "Martin"
            },
            {
                "email": "khan.m.imran@outlook.com",
                "first": "M. Imran",
                "initial": "M.I.",
                "last": "Khan"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.03.072",
        "firstpage": "2907",
        "issn": "0264410X",
        "keywords": [
            "Africa",
            "Developing countries",
            "Pediatric infections",
            "S. Enteritis",
            "S. Typhimurium",
            "Salmonella",
            "Salmonella infections",
            "Vaccine development",
            "iNTS disease"
        ],
        "lastpage": "2910",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Nontyphoidal salmonella disease: Current status of vaccine research and development"
    }
}